Trial site
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- 28running trials
- 7closed trials
The trials here
What the 35 trials at this site are about, from their registry records.
- Conditions
- Liver and biliary tract cancer8 trials
- Colorectal cancer6 trials
- Gastric and oesophageal cancer5 trials
- Lung cancer5 trials
- Childhood cancers3 trials
- Metastatic breast cancer3 trials
- Triple-negative breast cancer2 trials
- Cervical cancer1 trial
- Head and neck cancer1 trial
- Hepatitis B1 trial
- Mesothelioma1 trial
- Multiple myeloma1 trial
- and 4 more
- Phase
- Phase 29 trials
- Phase 36 trials
- Phase 14 trials
- Phase 1/23 trials
- Early phase 11 trial
- Status
- Recruiting19 trials
- Completed6 trials
- Active, not recruiting4 trials
- Not yet recruiting3 trials
- Enrolling by invitation2 trials
- Terminated1 trial
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences18 trials
- Pfizer3 trials
- National Cancer Institute (NCI)2 trials
- Betta Pharmaceuticals Co., Ltd.1 trial
- Biotech Pharmaceutical Co., Ltd.1 trial
- and 10 more
Running trials
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
Recruiting
Recruiting
Recruiting
Recruiting
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Recruiting
Recruiting
Enrolling by invitation
Recruiting
mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors
Active, not recruiting
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Recruiting
Recruiting
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Enrolling by invitation
Recruiting
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Not yet recruiting
Recruiting
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
Active, not recruiting
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
Recruiting
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
Recruiting
Active, not recruiting
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Recruiting
the National Colorectal Cancer Cohort (NCRCC) Study: National Colorectal Cancer Research Consortium
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Liver and biliary tract cancer7 recruiting
- Colorectal cancer5 recruiting
- Childhood cancers3 recruiting
- Gastric and oesophageal cancer3 recruiting
- Lung cancer3 recruiting
- Head and neck cancer1 recruiting
- Hepatitis B1 recruiting
- Mesothelioma1 recruiting
- Metastatic breast cancer1 recruiting
- Multiple myeloma1 recruiting
- Neuroendocrine tumours1 recruiting
- Ovarian cancer1 recruiting
- Pancreatic cancer1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Site data: ClinicalTrials.govUpdated 12 Nov 2026